Last synced from Twitter 90d ago
SOHC Swiss Oncology and Hematology Congress 2020, 18 - 21 November 2020
Oliver Gautschi
Selpercatinib LIBRETTO-001 accepted for 2 oral presentations at #SOHC2020 - Swiss Oncology and Hematology Congress @weiler_daniela @LillyPad @loxooncology @alexdrilon @VivekSubbiah
92d
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Purpose The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in...
DGHO 2020
1
Oliver Gautschi
Honored to present LIBRETTO-001 results at the #DGHO2020 conference on behalf of the whole trial team (oral abstract 87) @LillyPad @loxooncology @alexdrilon @VivekSubbiah
107d
DGHO 2020
Oliver Gautschi
Honored to present LIBRETTO-001 results at the #DGHO20 conference on behalf of the whole trial team @LillyPad @loxooncology @alexdrilon @VivekSubbiah
107d
ITOG – Innsbruck Thoracic Oncology Group
1
Oliver Gautschi
Thank you ITOG for todays Webinar (in German) about new targeted therapies with top presentations by Dr Pall, Scheffler and Heukamp @ITOG3 @trnsltnl @LHeukamp
111d
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
Over the past few years, immune checkpoint inhibitors have changed the therapeutic landscape of non-small-cell lung cancer (NSCLC). Response to immune checkpoint inhibitors correlates with a pre-existing anti-tumoral immune response. Checkpoint...
Oliver Gautschi
Chemotherapy negatively impacts tumor immune microenvironment in NSCLC @SAKK_ch #LCSM @MdCurioni @peters_solange @RothschildSacha @unibern
116d
Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer
Rearranged during transfection (RET) gene fusions are a validated target in non-small
cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib
(BLU-667) recently demonstrated favorable antitumor activity and safety...
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
Our results support the addition of neoadjuvant nivolumab to platinum-based chemotherapy
in patients with resectable stage IIIA NSCLC. Neoadjuvant chemoimmunotherapy could
change the perception of locally advanced lung cancer as a potentially lethal...
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOU
Receptor activator of NF-kB ligand stimulates NF-kB–dependent cell signaling and acts as the primary signal for bone resorption. Retrospective analysi…
Oliver Gautschi
SPLENDOUR: Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC @JTOonline @ETOP_eu @EORTC @gecp_org @SAKK_ch @peters_solange @MdCurioni @BenjaminBesseMD @bmassutis
123d
Time to Rethink Oncology Clinical Research
This Viewpoint discusses how the COVID-19 pandemic may reshape clinical practice and clinical research as new technologies are incorporated and old practices are revisited and revamped.
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Original Article from The New England Journal of Medicine — Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
Selpercatinib Aimed at RET-Altered Cancers | NEJM
Editorial from The New England Journal of Medicine — Selpercatinib Aimed at RET-Altered Cancers
1
Oliver Gautschi
Selpercatinib Aimed at RET-Altered Cancers : Editorial by @Dr_R_Kurzrock @NEJM
153d
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers | NEJM
Original Article from The New England Journal of Medicine — Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Oliver Gautschi
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers : L. Wirth & M. Cabanillas @NEJM @alexdrilon @bensolomon1 @VivekSubbiah @barlesi @danieltanmd
153d
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer | NEJM
Original Article from The New England Journal of Medicine — Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
1
Oliver Gautschi
#Selpercatinib @alexdrilon @geoff_oxnard @JustinGainor @n8pennell @MLJohnsonMD2 @VamsiVelcheti @BenjaminBesseMD @barlesi @VivekSubbiah @herbloong @bensolomon1
153d
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Introduction: Survival of ALK-rearranged NSCLC patients has dramatically improved by the use of multiple ALK-tyrosine kinase inhibitors (ALK-TKI). However, still little is known about the impact of drug sequencing and clinical features on survival...
1
Oliver Gautschi
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer @MdCurioni @Alfdoc2 @gbanna74 @RothschildSacha
157d
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+…
A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial
RANKL stimulates NF-kB-dependent cell-signalling and acts as the primary signal for
bone resorption. Retrospective analysis of a large trial comparing denosumab versus
zoledronic acid in bone metastatic solid tumours suggested significant overall...
1
Oliver Gautschi
SPLENDOUR trial published @JTOonline @peters_solange @drMaryOBr @lindacoate @cczielinski @MdCurioni @BenjaminBesseMD @JessicaMenis @ETOP_eu @EORTC @SAKK_ch
220d
Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
MNNG HOS Transforming gene (MET) amplification is a recurrent genetic alteration associated
with acquired resistance to EGFR tyrosine kinase inhibitor therapy in patients with
EGFR-mutant NSCLC. As published the Journal of Thoracic Oncology,...
Oliver Gautschi
@JFreemanDaily @lgreco_ny @ros1cancer @rdoebele @DrMarkAwad @alexdrilon @METCrusaders Capmatinib is potentially available via the Novartis MAP. I am currently treating two patients with EGFR/MET NSCLC with cap/osi, one of them was reported here
237d